Amgen Ventures is the venture capital arm of Amgen Inc., focusing on investments in early-stage and later-stage biotechnology companies. The firm aims to discover and develop human therapeutics, emphasizing areas such as oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. Specific areas of interest in oncology and hematology include novel therapeutics related to signal transduction, cell cycle regulation, and supportive care. In nephrology, the focus is on renal failure, while inflammation targets diseases such as rheumatoid arthritis and multiple sclerosis. Cardiovascular investments address acute coronary syndromes and heart failure, and metabolic disorder investments include diabetes and osteoporosis. The firm also engages in early-stage drug discovery collaborations and innovative technologies. Amgen Ventures primarily operates in North America, Europe, and the United Kingdom, typically investing between $2 million and $3 million per transaction, with a potential maximum of $10 million per company, while preferring an ownership stake of less than 15%. Established in 2004, Amgen Ventures is headquartered in San Francisco, California, with additional offices in Seattle, Thousand Oaks, and Cambridge.